Cyprus IP Box Requirements & Substance (2026)

Who can claim the Cyprus IP Box?

The regime is available to a Cyprus tax-resident company that owns qualifying intellectual property and earns income from it. It is a corporate relief: individuals, sole traders and partnerships cannot claim in their own right, so the IP must sit inside a company that is genuinely managed and taxed in Cyprus.

Tax residency turns on where the company is effectively managed and controlled, not merely where it is registered. A company incorporated in Cyprus but run from abroad may fail this test and, with it, the whole claim.

• Claimant must be a company that is tax-resident in Cyprus.
• Individuals, sole traders and partnerships are not eligible.
• The company must own the qualifying IP and derive income from it.
• Tax residency depends on management and control being exercised in Cyprus.

What counts as qualifying IP?

Only certain classes of IP qualify. The regime targets IP that results from genuine research and development, which is why marketing-related rights are deliberately excluded.

If your value sits in a brand rather than in developed technology, the IP Box will not help; you would need to restructure the underlying IP or rely on other reliefs.

• Patents.
• Copyrighted software.
• Utility models.
• Plant breeders' rights and genetic material.
• Orphan-drug designations.
• Other IP that is non-obvious, useful and novel, and certified as such.
• Not qualifying: trademarks, brands, image rights and other marketing-related IP.

You must fund the R&D: the nexus rule

The benefit is not automatic on qualifying IP; it is scaled by how much of the development you actually funded. This is the modified nexus approach, and it is the single most important quantitative requirement.

The nexus fraction is (your own qualifying R&D spend + R&D outsourced to unrelated parties + a 30% uplift) divided by total qualifying spend on the asset, capped at 100%. Costs such as acquisition of the IP and R&D outsourced to related parties dilute the fraction, so buying in finished IP or having a group company do the work reduces the relief.

Because the ratio is tracked per asset, the practical consequence is that companies which develop their own IP with their own people, or with independent contractors, keep the most benefit.

• Nexus ratio = (own R&D + unrelated-party R&D + 30% uplift) / total spend.
• The ratio is capped at 100%.
• Acquisition costs and related-party outsourcing reduce the fraction.
• Track qualifying and total expenditure separately for each IP asset.

Economic and tax-residency substance in Cyprus

A qualifying company on paper is not enough. Tax authorities expect genuine substance: the company must really operate from Cyprus, not simply hold a registered address there.

Substance protects both the IP Box claim and the underlying Cyprus tax residency. The level required scales with the size and profile of the business, but the direction of travel is the same: real people making real decisions in Cyprus.

• Management and control exercised in Cyprus: board meetings held and decisions taken locally.
• A majority of directors resident in Cyprus, with genuine decision-making authority.
• A real office in Cyprus, proportionate to the activity, where this is warranted.
• Local staff or independent contractors performing the actual R&D and operations.
• Cyprus banking and day-to-day financial control run from Cyprus.
• Substance sized to the scale of the business, not a nominal presence.

Documentation kept contemporaneously

The IP Box is a self-assessed relief, so the burden of proof sits with you. Records must be created as the work happens, not reconstructed later when a query arrives, and they must let you trace income and costs to each individual asset.

Good documentation is also what makes the nexus calculation defensible. If you cannot show who did the R&D and what it cost per asset, the fraction can be challenged and the relief reduced or denied.

• A development history for each asset showing how and when it was created.
• Evidence of who performed the R&D: employees, contractors and their roles.
• Per-asset income and cost tracking, kept separate from other activities.
• Timesheets and project logs linking hours to specific IP.
• Code repositories, commit logs and version histories for software.
• Contracts with contractors and evidence that unrelated-party status is genuine.
• Records retained contemporaneously and available for the statutory period.

Common reasons claims fail

Most failed or reduced claims come down to a handful of recurring problems. Knowing them in advance is the cheapest form of insurance.

Almost all of these are avoidable with planning at the outset, before income starts to flow through the structure.

• Trying to claim through an individual or partnership rather than a company.
• Treating a trademark or brand as qualifying IP.
• Acquiring finished IP or outsourcing R&D to related parties, crushing the nexus ratio.
• Thin substance: no local decision-making, no office, no staff in Cyprus.
• No per-asset cost tracking, so the nexus fraction cannot be evidenced.
• Records assembled after the fact rather than kept contemporaneously.
• Management and control located abroad, undermining Cyprus tax residency.

What the regime is worth in 2026

The IP Box allows 80% of qualifying profit (as scaled by the nexus fraction) to be deducted, leaving only the balance subject to corporation tax. Against the 2026 headline corporate rate, this brings the effective rate on qualifying IP income down to roughly 3%.

That figure is indicative and assumes a full nexus fraction and clean substance. The actual outcome depends on your cost mix, your funding of the R&D and the quality of your documentation, so model it on your own numbers before relying on it.